Insider Selling: CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Major Shareholder Sells 850,543 Shares of Stock

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) major shareholder Bioventures Opportunities G. Yk sold 850,543 shares of the firm’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $0.11, for a total value of $93,559.73. Following the transaction, the insider now directly owns 20,533,366 shares in the company, valued at approximately $2,258,670.26. This represents a 3.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

CERo Therapeutics Stock Performance

Shares of NASDAQ CERO traded down $0.02 during midday trading on Tuesday, reaching $0.09. 16,480,674 shares of the company were exchanged, compared to its average volume of 20,468,281. CERo Therapeutics Holdings, Inc. has a 1 year low of $0.06 and a 1 year high of $12.80. The stock has a fifty day simple moving average of $0.13 and a 200 day simple moving average of $0.23.

CERo Therapeutics Company Profile

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.